Figure 2

BALF and serum CC16 concentration. (A) Non sensitized (NS/UFP) and sensitized (S/UFP) mice exposed to EC-UFP, and treated with NAC (NS/NAC/UFP and S/NAC/UFP, respectively); (B) Sensitized and challenged mice (S/OVA), treated with NAC (S/NAC/OVA), or exposed to EC-UFP 24 h prior to OVA challenge (S/UFP/OVA), and treated with NAC (S/NAC/UFP/OVA). NAC treatment was performed prior to and close to mid EC-UFP exposure. Untreated mice served as baseline controls (dotted line). Data presented as mean ± SD (n = 4-7/time point). *p < 0.05, **p < 0.01 vs untreated; ⁺⁺p < 0.01 vs S/UFP;^#p < 0.05, ^##p < 0.01 NS/UFP, S/UFP, S/OVA, S/NAC/UFP/OVA vs S/UFP/OVA.